Advances in gene transfer into haematopoietic stem cells by adenoviral vectors

Expert Opinion on Biological Therapy

Volumn 2, Issue 8, 2002, Pages 847-856

  C Marini, Frank ^a   Shayakhmetov, Dmitry ^b   Gharwan, Helen ^b   Lieber, Andre ^b   Andreeff, Michael ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus; Capsid proteins; Gene therapy; Haematopoietic stem cells; Retargeting; Vector polycation complex

Indexed keywords

ADENOVIRUS VECTOR; CAPSID PROTEIN; CIS ACTING ELEMENT; POLYMER;

AMINO ACID SEQUENCE; CELL INTERACTION; CLINICAL TRIAL; DNA MODIFICATION; FIBER; GENE TRANSFER; GENETIC TRANSDUCTION; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; POLYMERIZATION; REVIEW; VIRUS HYBRID;

ADENOVIRIDAE; ANIMALS; CAPSID PROTEINS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HUMANS;

ADENOVIRIDAE; MIRIDAE;

EID: 0036919337     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2.8.847     Document Type: Review

References (73)

1. Bertrand D: Gene therapy may lead to cure for sickle cell patients. J. Natl. Med. Assoc. (2002) 94(4):A9-A10.
2. Tisdale J, Sadelain M: Toward gene therapy for disorders of globin synthesis. Semin. Hematol. (2001) 38(4):382-392.
3. Emery DW, Nishino T, Murata K, Fragkos M, Stamatoyannopoulos G: Hematopoietic stem cell gene therapy. Int. J. Hematol. (2002) 75(3):228-236.
4. Miller DG, Stamatoyannopoulos G: Gene therapy for hemophilia. N. Engl. J. Med. (2001) 344(23):1782-1784.
5. Bordignon C, Roncarolo MG: Therapeutic applications for hematopoietic stem cell gene transfer. Nat. Immunol. (2002) 3(4):318-321. Reviews all the current paradigms and applications of gene transfer in HSC.
6. Melo ME, El-Amine M, Tonnetti L, Fleischman L, Scott DW: Gene therapeutic approaches to induction and maintenance of tolerance. Int. Rev. Immunol. (2001) 20(5):627-645.
7. Mackiewicz A, Kapcinska M, Wiznerowicz M et al.: Immunogene therapy of human melanoma. Phase I/II clinical trial. Adv. Exp. Med. Biol. (1998) 451:557-560.
8. Kohn DB: Gene therapy for genetic haematological disorders and immunodeficiencies. J. Intern. Med. (2001) 249(4):379-390.
9. Scherr M, Eder M: Gene transfer into hematopoietic stem cells using lentiviral vectors. Curr. Gene Ther. (2002) 2(1):45-55.
10. Nathwani AC, Hanawa H, Vandergriff J, Kelly P, Vanin EF, Nienhuis AW: Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38-subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV. Gene Ther. (2000) 7(3):183-195.
11. Medin JA, Fowler DH: Post-transduction events in retrovirus-mediated Gene therapy involving hematopoietic stem cells: Beyond efficiency issues. J. Cell Biochem. Suppl. (2002) 38:46-54.
12. Russell WC: Update on adenovirus and its vectors. J. Gen. Virol. (2000) 81(Pt 11):2573-2604. In-depth, highly detailed review article explaining the ins and outs of adenoviruses and their application as gene therapy vectors. Highly recommended.
13. Crystal RG, Mastrangeli A, Sanders A et al.: Evaluation of repeat administration of a replication deficient, recombinant adenovirus containing the normal cystic fibrosis transmembrane conductance regulator cDNA to the airways of individuals with cystic fibrosis. Hum. Gene Ther. (1995) 6(5):667-703. One of the first applications of Adv vectors in gene therapy.
14. Marini FC III, Cannon JP, Belmont JW, Shillitoe EJ, Lapeyre JN: In vivo marking of spontaneous or vaccine-induced fibrosarcomas in the domestic house cat, using an adenoviral vector containing a bifunctional fusion protein, GAL-TEK. Hum. Gene Ther. (1995) 6(9):1215-1223.
15. Lin T, GU J, Zhang L et al.: Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res. (2002) 62(13):3620-3625.
16. Kochanek S, Schiedner G, Volpers C: High-capacity 'gutless' adenoviral vectors. Curr. Opin. Mol. Ther. (2001) 3(5):454-463.
17. Ehrhardt A, Kay MA: Anew adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation Factor IX at low doses in vivo. Blood (2002) 99(11):3923-3930.
18. Kim IH, Jozkowicz A, Piedra PA, Oka K, Chan L: Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc. Natl. Acad. Sci. USA (2001) 98(23):13282-13287.
19. Morsy MA, Gu M, Motzel S et al.: An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. USA (1998) 95(14):7866-7871.
20. Roitsch C, Achstetter T, Benchaibi M et al.: Characterization and quality control of recombinant adenovirus vectors for gene therapy. J. Chromatogr B. Biomed. Appl. (2001) 752(2):263-280.
21. Cao B, Mytinger JR, Huard J: Adenovirus mediated gene transfer to skeletal muscle. Microsc. Res. Tech. (2002) 58(1):45-51.
22. Zou L, Zhou H, Pastore L, Yang K: Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system. Mol. Ther. (2000) 2(2):105-113.
23. Knaan-Shanzer S, Van Der Velde I, Havenga MJ, Lemckert AA, De Vries AA, Valerio D: Highly efficient targeted transduction of undifferentiated human hematopoietic cells by adenoviral vectors displaying fiber knobs of subgroup B. Hum. Gene Ther. (2001) 12:1989-2005. A very thorough study of multiple capsid-modified Adv vectors as a vehicle for HSCs.
24. Nathwani AC, Persons DA, Stevenson SC et al.: Adenovirus-mediated expression of the murine ecotropic receptor facilitates transduction of human hematopoietic cells with an ecotropic retroviral vector. (1999) Gene Ther. 6:1456-1468. The first paper describing application of Adv vector with fibres derived from human Adv serotype 3 for gene transfer into HSCs.
25. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A: Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J. Virol. (2000) 74:2567-2583. First detailed analyses demonstrating the capacity of capsid-modified Adv vector with Ad35 derived fibre protein to efficiently transduce broad subsets of human HSC, including CD34+/c-kit+ cells, in a CAR and αv integrin independent manner.
26. Recchia A, Parks RJ, Lamartina S, Toniatti C et al.: Site-specific integration mediated by a hybrid adenovirus/adeno- associated virus vector. Proc. Natl. Acad. Sci USA (1999) 96:2615-2620.
27. Wattel E, Vanrumbeke M, Abina MA et al.: Differential efficacy of adenoviral mediated gene transfer into cells from hematological cell lines and fresh hematological malignancies. Leukemia (1996) 10(1):171-174.
28. Roelvink PW, Lizonova A, Lee JG et al.: The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J. Virol. (1998) 72(10):7909-7915.
29. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR: Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell (1993) 73(2):309-319.
30. Marini FC III, YU Q, Wickham T, Kovesdi I, Andreeff M: Adenovirus as a gene therapy vector for hematopoietic cells. Cancer Gene Ther. (2000) 7(6):816-825. Interesting - goes into depth about the initial controversy on whether wild-type Advs do infect HSC.
31. Rebel VI, Hartnett S, Denham J, Chan M, Finberg R, Sieff CA: Maturation and lineage-specific expression of the coxsackie and adenovirus receptor in hematopoietic cells. Stem Cells (2000) 18(3):176-182. Detailed study of CAR expression during haematopoietic lineage differentiation.
32. Neering SJ, Hardy SF, Minamoto D, Spratt SK, Jordan CT: Transduction of primitive human hematopoietic cells with recombinant adenovirus vectors. Blood (1996) 88(4):1147-1155.
33. Mackenzie KL, Hackett NR, Crystal RG, Moore MA: Adenoviral vector-mediated gene transfer to primitive human hematopoietic progenitor cells: Assessment of transduction and toxicity in long-term culture. Blood (2000) 96(1):100-108.
34. Fan X, Brun A, Segren S, Jacobsen SE, Karlsson S: Efficient adenoviral vector transduction of human hematopoietic SCID-repopulating and long-term culture-initiating cells. Hum. Gene Ther. (2000) 11(9):1313-1327.
35. Fan X, Brun A, Karlsson S: Adenoviral vector design for high-level transgene expression in primitive human hematopoietic progenitors. Gene Ther. (2000) 7(24):2132-2138.
36. Jordan CT, Vanin EF, Marini FC: The use of adenoviral vectors for genetic manipulation and analysis of primitive hematopoietic cells. Curr. Gene Ther. (2001) 1(3):257-265.
37. Frey BM, Hackett NR, Bergelson JM et al.: High-efficiency gene transfer into ex vivo expanded human hematopoietic progenitors and precursor cells by adenovirus vectors. Blood (1998) 91:2781-2792.
38. Byk T, Haddada H, Vainchenkerw, Louache F: Lipofectamine and related cationic lipids strongly improve adenoviral infection efficiency of primitive human hematopoietic cells. Hum. Gene Ther. (1998) 9(17):2493-2502. This study compares both viral particles/cell efficiency and promoter activity in HSC.
39. Di Nicola M, Carlo-Stella C, Milanesi M et al.: Large-scale feasibility of gene transduction into human CD34+ cell-derived dendritic cells by adenoviral/polycation complex. Br. J. Haematol. (2000) 111(1):344-350.
40. Fasbender A, Zabner J, Chillon M et a.: Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J. Biol. Chem. (1997) 272:6479-6489.
41. Howard DS, Rizzierri D, Grimes B, et al.: Genetic manipulation of primitive leukemic and normal hematopoietic cells using a novel method of adenovirus-mediated gene transfer. Leukemia (1999) 13:1608-1616.
42. Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT: Targeted gene delivery by tropism-modified adenoviral vectors. Nat. Biotechnol. (1996) 14:1574-1548. First report of antibody redirected Advs.
43. Douglas JT, Miller CR, Kim M et al.: A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat. Biotechnol. (1999) 17:470-475.
44. Smith JS, Keller JR, Lohrey NC et al.: Redirected infection of directly biotinylated recombinant adenovirus vectors through cell surface receptors and antigens. Proc. Natl. Acad. Sci. USA (1999) 96:8855-8860. Interesting study demonstrating the application of antibody redirection towards haematopoietic cells.
45. Stecher H, Shayakhmetov DM, Stamatoyannopoulos G, Lieber A: A capsid-modified adenovirus vector devoid of all viral genes: assessment of transduction and toxicity in human hematopoietic cells. Mol. Ther. (2001) 4:36-44.
46. Yotnda P, Onishi H, Heslop HE et al.: Efficient infection of primitive hematopoietic stem cells by modified adenovirus. Gene Ther. (2001) 8:930-937. Important data demonstrating the ability of capsid-modified Adv to deliver transgenes into human SP cells with low toxicity.
47. Roelvink PW, Kovesdi I, Wickham TJ. Comparative analysis of adenovirus fiber-cell interaction: Adenovirus Type 2 (Ad2) and Ad9 utilize the same cellular fiber receptor but use different binding strategies for attachment. J. Virol. (1996) 70(11):7614-7621.
48. Einfeld DA, Schroeder R, Roelvink PW et aL: Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J. Virol. (2001) 75(23):11284-11291.
49. Roelvink PW, Mi Lee G, Einfeld DA, Kovesdi I, Wickham TJ: Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science (1999) 286(5444):1568-1571. This report describes the specific amino adds which permit the CAR/fibre interaction to occur and details what needs to be mutated to ablate this binding activity.
50. Kirby I, Davison E, Beavil AJ et al.: Mutations in the DG loop of adenovirus Type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR. J. Virol. (1999) 73(11):9508-9514.
51. Kasono K, Blackwell JL, Douglas JT et al.: Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin. Cancer Res. (1999) 5(9):2571-2579.
52. Wickham TJ, Roelvink PW, Brough DE, Kovesdi I: Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat. Biotechnol. (1996) 14(11):1570-1573. First report of polylysine incorporation into fibre demonstrating redirection with an Adv.
53. Wickham TJ, Tzeng E, Shears LL II et al.: Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. (1997) 71(11):8221-8229.
54. Gonzalez R, Vereecque R, Wickham TJ et al.: Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein. Gene Ther. (1999) 6(3):314-320.
55. Gonzalez R, Vereecque R, Wickham TJ et al.: Transduction of bone marrow cells by the AdZ.F(pK7) modified adenovirus demonstrates preferential gene transfer in myeloma cells. Hum. Gene Ther. (1999) 10(16):2709-2717.
56. Garcia-Castro J, Segovia JC, Garcia-Sanchez F et al.: Selective transduction of murine myelomonocytic leukemia cells (WEHI-3B) with regular and RGD-adenoviral vectors. Mol. Ther. (2001) 1:70-77. This report describes the use of an RGD fibre-modified Adv, and demonstrates its increased efficiency in haematopoietic cells.
57. Asada-Mikami R, Heike Y, Kanai S et al.: Efficient gene transduction by RGD-fiber modified recombinant adenovirus into dendritic cells. Jpn. J. Cancer Res. (2001) 92(3):321-327.
58. Kushida T, Inaba M, Hisha H et al.: Intra-bone marrow injection of allogeneic bone marrow cells: A powerful new strategy for treatment of intractable autoimmune diseases in MRL/lpr mice. Blood (2001) 97(10):3292-3299.
59. Thorsteinsdottir U, Mamo A, Kroon E et al.: Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood (2002) 99:121-129.
60. Ueno T, Matsumura H, Tanaka K et al.: Site-specific integration of a transgene mediated by a hybrid adenovirus/adeno-associated virus vector using the Cre/loxP-expression-switching system. Biochem. Biophys. Res. Commun. (2000) 273:473-478.
61. Steinwaerder DS, Carlson CA, Lieber A: Generation of adenovirus vectors devoid of all viral genes by recombination between inverted repeats. J. Virol. (1999) 73:9303-9313.
62. Carlson CA, Steinwaerder DS, Stecher H, Shayakhmetov DM, Lieber A: Rearrangements in adenoviral genomes mediated by inverted repeats. Methods Enzymol. (1999) 346:277-292.
63. Lieber A, Steinwaerder DS, Carlson CA, Kay MA: Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes. J. Virol. (1999) 73:9314-9324.
64. Shayakhmetov DM, Carlson CA, Stecher H, Li Q, Stamatoyannopoulos G, Lieber A: A high-capacity, capsid-modified hybrid adenovirus/adeno-associated virus vector for stable transduction of human hematopoietic cells. J. Virol. (2002) 76:1135-1143.
65. Zheng C, Baum BJ, Iadarola MJ, O'Connell BC: Genomic integration and gene expression by a modified adenoviral vector. Nat. Biotechnol. (2000) 18:176-180.
66. Zheng C, Baum BJ: Long-term expression after infection by the hybrid vector AdLTR-luc is from integrated transgene. Biochem. Biophys. Res. Commun. (2002) 291:34-40.
67. Yant SR, Meuse L, Chiu W, Ivics Z, Izsvak Z, Kay MA: Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA rransposon system. Nat. Genet. (2000) 25:35-41. Interesting report describing a transposon based integration system for Adv.
68. Davis BM, Koc ON, Gerson SL: Limiting numbers of G156A O(6)-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection. Blood (2000) 95:3078-3084.
69. Davis BM, Encell LP, Zielske SP et al.: Applied molecular evolution of O6-benzylguanine-resistant DNA alkyltransferases in human hematopoietic cells. Proc. Natl. Acad Sci. USA (2001) 98:4950-4954.
70. Neff T, Blau CA: Pharmacologically regulated cell therapy. Blood (2001) 97:2535-2540.
71. Koivunen E, Ranta TM, Annila A et al.: Inhibition of beta(2) integrin-mediated leukocyte cell adhesion by leucine-leucine-glycine motif-containing peptides. J. Cell Biol. (2001) 153(5):905-916.
72. Tseng-Law J, Szalay P, Guillermo R et al.: Identification of a peptide directed against the anti-CD34 antibody, 9C5, by phage display and its use in hematopoietic stem cell selection. Exp. Hematol. (1999) 27(5):936-945.
73. Krasnykh V, Belousova N, Korokhov N, Mikheeva G, Curiel DT: Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J. Virol. (1999) 75(9):4176-4183. Interesting report demonstrating that bacteriophage T4 fibritin can replace Adv fibre. Of note is that fibritin appears to allow incorporation of very large peptides without distortion, whereas incorporation of 8 - 10 amino acids appears to be the maximum allowed into the HI of Adv fibre.